National Numeracy Day 2024: making maths work for women and girls

May 22, 2024

Written by Abby Paine, Hollie Pilkington, and Dom Partridge

 

Two years ago we wrote a blog for National Numeracy Day 2022, and enjoyed the process so much that we thought we would write another one! Last time, we wrote about network meta-analyses (a statistical method we use quite a lot here at Source), but this year we thought we’d introduce you to some of the women in our teams, who use maths as a key part of their everyday jobs. We have female colleagues working in both the health economics and statistics teams – in fact they make up 50% of the staff in those teams!

All of our health economists and statisticians play a key role in the launch of new medical treatments. For any new medicine to be approved for use in a particular disease, it must be more effective and at least as safe as an existing successful treatment (or a placebo). Statisticians review the available clinical trial data to determine whether a new treatment is better due to a placebo effect, or whether the additional benefit is real. Health economists use maths to consider how the effectiveness of the treatment compares with its cost, which is really important because while healthcare services around the world want the best treatment for their patients, they are constrained by budget pressures and need to determine what is the best use of their budgets when they have so many patients to treat.

One of the focuses for this year’s National Numeracy Day is making maths work for women and girls. We spoke to some of our female team members to get an insight into their experiences and hope this might encourage other women (and everyone!) to get into maths because it gives you so many career options:

 

 

If you are interested in exploring a career in health economics and market access, consider connecting with the Economic Modelling and Data Analysis team at Source Health Economics; we specialise in evidence generation, health economics, and communication.

More Insights

HTA quarterly update

HTA quarterly update

Written by Ben Clark, Paloma Charlesworth, and Kiera Lander   This quarterly update highlights recent and upcoming developments shaping the health technology assessment (HTA) environment across Europe, with a particular focus on rare ... Read more

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Written by Jo Wallis, Head of Commercialisation and Pricing Strategy   The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the ... Read more

The role of orphan drug designations in driving research and innovation for rare diseases

The role of orphan drug designations in driving research and innovation for rare diseases

Written by Emma Bartram, Associate Systematic Review Analyst   A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). ... Read more

HTA monthly update

HTA monthly update

By Toby Hobbs   Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment ... Read more